Dilated Cardiomyopathy
Introduction
Dilated cardiomyopathy (DCM) is a significant and prevalent form of heart muscle disease characterized by the enlargement (dilation) of one or both ventricles of the heart, particularly the left ventricle, accompanied by impaired pumping function (systolic dysfunction). [1] It is a major cause of heart failure, a condition affecting a substantial number of individuals annually, with nearly half of these cases not attributed to ischemic heart disease. [2] DCM is a leading indication for heart transplantation in advanced cases. [3] The classification and management of cardiomyopathies, including DCM, are guided by international consensus statements and clinical guidelines. [4]
Biological Basis
The biological underpinnings of DCM are complex and multifactorial, involving a combination of genetic, environmental, and other non-genetic influences. [2] Genetic factors are recognized as substantial contributors, with familial cases accounting for at least 30% of idiopathic DCM diagnoses. [2] However, the precise etiology remains undetermined in many cases, even after extensive genetic screening. [2] Research indicates that mutations in various genes can lead to DCM, and conversely, mutations within the same gene can manifest in diverse clinical presentations of cardiomyopathy, highlighting the complex interplay of genetic and modifying factors. [2] The estimated heritability of DCM is approximately 31%. [5]
Key genes implicated in DCM include those encoding sarcomeric proteins, such as MYBPC3, MYH6, TPM1, TNNC1, and TNNI3, where rare coding sequence variants have been identified in familial or idiopathic DCM patients. [6] Genome-wide association studies (GWAS) have further elucidated the genetic landscape, identifying susceptibility loci such as those involving HSPB7 and BAG3. [7] HSPB7 (also known as cardiovascular HSP) is a small heat shock protein selectively expressed in cardiovascular tissues, and its genetic variants are associated with advanced heart failure and systolic dysfunction. [7] More recent GWAS have discovered additional loci on chromosomes 3p25.1 and 22q11.23, with candidate culprit genes identified as SLC6A6 and SMARCB1 respectively, shedding light on novel biological pathways. [5] A novel risk locus for DCM has also been identified at 6p21. [8] Recent research integrates GWAS with single-cell data to identify plausible gene candidates for cardiomyopathy and left ventricular function, including genes involved in calcium handling like CAMK2D. [9]
Clinical Relevance
DCM is a critical clinical entity primarily leading to systolic heart failure. [9] The diagnostic process often involves phenotypic refinement to better characterize heart failure subtypes, which aids in genetic discovery. [10] Genetic testing is increasingly utilized to assess diagnostic yield for combined cardiomyopathy and arrhythmia conditions. [11] Current clinical guidelines provide comprehensive recommendations for the diagnosis and management of cardiomyopathies. [4] Identifying genetic risk factors for DCM also contributes to understanding the genetic liability to systolic heart failure and may modulate risk across various clinical settings. [9] Potential causal risk factors identified through Mendelian randomization studies include weight, body mass index (BMI), atrial fibrillation (AF), and systolic blood pressure (SBP). [9]
Social Importance
DCM represents a significant public health challenge due to its association with heart failure, a condition that contributes to a substantial number of deaths and new diagnoses annually. [2] The disease severely impacts patients' quality of life and imposes a considerable burden on healthcare systems. Advances in understanding the genetic determinants and mechanisms of DCM are crucial for developing improved diagnostic tools, risk stratification strategies, and targeted therapies. [9] Insights from genetic research, including the identification of novel biological pathways and potential new therapeutic targets, hold promise for enhancing patient outcomes and reducing the overall societal impact of this debilitating heart condition. [5]
Methodological and Statistical Considerations
The power of genome-wide association studies (GWAS) is inherently tied to sample size, and while the meta-analysis for dilated cardiomyopathy (DCM) included a substantial number of cases (5,521 cases and 397,323 controls), smaller individual studies contributing to the overall understanding of DCM have historically been limited in their power, identifying only a handful of significant loci. [9] The use of multi-trait analysis of GWAS (MTAG) effectively increased the statistical power, boosting the effective sample size by approximately 73% for DCM. [9] However, despite these advancements, there remains a maximum false-discovery rate of 0.03 for MTAG, meaning a small percentage of signals could represent false positives under less favorable conditions. [9]
Furthermore, while genomic inflation factors (λ) were reported as 1.028 for single-trait analysis and 1.049 for MTAG [12] and LD score regression was used to quantify residual inflation, these metrics indicate that some degree of confounding or polygenicity may still influence results. [9] The replication of findings, particularly from prior smaller studies or for specific variants, can be challenging, as evidenced by some replication cohorts having limited sample sizes, which could affect the robustness and generalizability of individual variant associations. [5] These statistical nuances highlight the need for continued large-scale studies and rigorous validation to solidify causal inferences and refine effect size estimates.
Phenotypic Heterogeneity and Ancestral Bias
A significant limitation in genetic studies of DCM stems from the inherent heterogeneity in its clinical definition and measurement, which can impact discovery yield. The choice of a strict non-ischemic dilated cardiomyopathy (NI-DCM) phenotype was found to offer a greater discovery yield compared to a broader non-ischemic cardiomyopathy (NICM) definition, despite the latter having substantially larger case numbers. [9] This underscores the challenge of consistent phenotyping, where diagnostic criteria—such as reduced ejection fraction and enlarged left ventricular end-diastolic volume/diameter—can vary or be influenced by confounding factors like ventricular geometry, potentially introducing subtle biases in case ascertainment. [5]
Additionally, the generalizability of these genetic findings is primarily constrained by the ancestral composition of the study cohorts. The Mendelian randomization analyses, for instance, specifically utilized GWAS summary statistics largely derived from populations of European ancestry to ensure comparable linkage disequilibrium structures. [9] While some efforts included control subjects of North African or Turkish origin for specific variant sequencing, the predominant focus on European populations limits the direct applicability and transferability of these genetic insights to diverse global populations, potentially overlooking important ancestry-specific genetic architectures or allele frequencies relevant to DCM. [7]
Complex Etiology and Unexplained Variation
Dilated cardiomyopathy is a complex disorder influenced by a combination of genetic and non-genetic factors, and current research still faces challenges in fully unraveling its intricate etiology. While Mendelian randomization identified several potential causal risk factors for DCM, such as weight, body mass index, atrial fibrillation, and systolic blood pressure, these findings often reflect genetic predispositions to risk factors rather than direct environmental confounders. [9] The precise interplay between these genetically influenced traits and external environmental exposures in the development and progression of DCM remains an area requiring further investigation, as gene-environment interactions are not fully elucidated within the current framework.
Furthermore, a significant portion of the heritability of complex traits like DCM often remains unexplained by identified common genetic variants, a phenomenon known as "missing heritability". [13] Although the integration of GWAS with single-cell data has begun to identify plausible gene candidates for cardiomyopathy and left ventricular function, these efforts represent initial steps toward a comprehensive understanding of disease mechanisms. [9] The recognition that polygenic risk scores may have differing contributions in carriers versus non-carriers of rare pathogenic variants also highlights the remaining knowledge gaps regarding the full spectrum of genetic architecture and the mechanisms underlying myocardial resilience in DCM. [9]
Variants
The BAG3 gene encodes a co-chaperone protein that plays a crucial role in cellular stress response, protein quality control, and selective autophagy, mechanisms essential for maintaining the health of muscle cells, including those in the heart. Variants in BAG3 are significantly associated with dilated cardiomyopathy (DCM), a condition characterized by an enlarged and weakened heart muscle. For instance, the non-synonymous single nucleotide polymorphism (SNP) rs2234962 (c.T757C, p.C151R) in BAG3 has been linked to a reduced risk of DCM, suggesting a protective effect of the arginine allele at position 151 of the BAG3 protein. [7] This variant is in complete linkage disequilibrium with rs61869036, a lead SNP identified in genome-wide association studies (GWAS) for DCM. [5] Beyond common variants, rare mutations in BAG3 have also been found in patients with familial forms of DCM, highlighting the gene's critical role in maintaining cardiac integrity. [7] While rs72842207 and rs72840788 are also located within the BAG3 locus, their specific functional impact on protein activity or direct association with DCM risk requires further investigation, although they are presumed to contribute to the overall genetic susceptibility through their proximity to regulatory or coding regions.
The HSPB7 gene, also known as cardiovascular heat shock protein, is selectively expressed in heart tissues and belongs to the small heat shock protein (sHSP) family, which helps bind and refold denatured proteins, protecting cells from stress-induced damage. [7] Genetic variants in HSPB7, such as rs1763605, have been associated with advanced heart failure and systolic dysfunction, indicating its importance in cardiac resilience. This gene has been consistently identified and confirmed as a susceptibility locus for DCM in large-scale genetic studies. [5] Another significant locus for DCM involves variants downstream of LSM3, including rs62232870, located on chromosome 3p25.1. [5] The LSM3 gene is part of the LSM (Like Sm) protein family, involved in RNA processing and degradation, which are fundamental cellular mechanisms. While rs62232870 itself is not an expression quantitative trait locus (eQTL) for nearby genes, other SNPs in its linkage disequilibrium block are significantly associated with the expression and methylation levels of genes like SLC6A6, suggesting indirect regulatory effects on cardiac function. [5] The roles of rs17226476 and rs6807275, near LSM3 and the long non-coding RNA LINC01267, likely involve influencing gene regulation or RNA stability, thereby contributing to DCM susceptibility.
Variants within the TTN gene, which encodes the colossal protein titin, a critical component of cardiac muscle sarcomeres, are well-established contributors to various cardiomyopathies, including dilated cardiomyopathy. [14] Titin acts as a molecular spring, providing elasticity and maintaining the structural integrity of muscle fibers, and disruptions in its function can severely impair heart contractility. While rs2042995 is a specific variant associated with this locus, its precise mechanism may involve affecting TTN protein structure or expression, or that of TTN-AS1, an antisense RNA that can modulate TTN gene activity. Similarly, the FLNC gene encodes filamin C, another large cytoskeletal protein that cross-links actin filaments and connects them to other cellular structures, playing a vital role in muscle cell mechanics and signal transduction. The variant rs2291569 in FLNC may alter protein stability, interactions, or expression, thereby contributing to myocardial weakness and the development of DCM, as mutations in FLNC are recognized causes of inherited cardiac conditions. [5] Both TTN and FLNC are central to the structural and functional integrity of the heart, making their genetic variations significant risk factors for DCM.
Beyond structural proteins, variations in genes involved in cellular regulation and signaling also contribute to DCM risk. The ZBTB17 gene, encoding a zinc finger and BTB domain-containing protein, functions as a transcription factor involved in cell proliferation, differentiation, and apoptosis, processes critical for cardiac development and response to stress. While rs10927875 is associated with this locus, its specific associations with DCM require further detailed study, though the gene's regulatory role suggests that variants could subtly alter gene expression pathways vital for myocardial health. [7] Similarly, CDKN1A, which codes for the cyclin-dependent kinase inhibitor 1A (p21), is a key regulator of the cell cycle and apoptosis, acting as a tumor suppressor and mediator of cellular senescence. The variant rs3176326 could influence cell cycle control or repair mechanisms in cardiac myocytes, impacting the heart's ability to cope with injury or stress, as outlined in general GWAS findings for DCM. [5] Coiled-coil domain containing 136 (CCDC136) is a less characterized gene, but its associated variants rs17165191 and rs4731517 may affect protein-protein interactions or cellular scaffolding, influencing cardiac cell architecture. Additionally, non-coding RNA genes such as RNU1-88P - Y_RNA and LINC00964 also harbor variants like rs4713999, rs12541595, and rs7461129, which can modulate gene expression or RNA stability, thereby indirectly influencing cardiac function and DCM susceptibility.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs2234962 rs72842207 rs72840788 |
BAG3 | dilated cardiomyopathy body height electrocardiography fatty acid-binding protein, heart measurement myosin-binding protein C, slow-type measurement |
| rs10927875 | ZBTB17 | dilated cardiomyopathy |
| rs3176326 | CDKN1A | atrial fibrillation hypertrophic cardiomyopathy QRS duration PR interval electrocardiography |
| rs17226476 rs62232870 rs6807275 |
LSM3 - LINC01267 | dilated cardiomyopathy |
| rs1763605 | SRARP - HSPB7 | serum gamma-glutamyl transferase measurement dilated cardiomyopathy |
| rs17165191 rs4731517 |
CCDC136 | dilated cardiomyopathy |
| rs4713999 | RNU1-88P - Y_RNA | dilated cardiomyopathy heart failure |
| rs2042995 | TTN-AS1, TTN | BMI-adjusted waist-hip ratio, sex interaction measurement dilated cardiomyopathy PR interval left ventricular diastolic function measurement left ventricular systolic function measurement |
| rs2291569 | FLNC | dilated cardiomyopathy |
| rs12541595 rs7461129 |
LINC00964 | left ventricular structural measurement dilated cardiomyopathy heart function attribute left ventricular systolic function measurement left ventricular ejection fraction measurement |
Definition and Core Characteristics of Dilated Cardiomyopathy
Dilated cardiomyopathy (DCM) is a myocardial disorder characterized by the enlargement and impaired systolic function of the left ventricle, or both ventricles, in the absence of other cardiac or systemic diseases sufficient to cause the observed myocardial abnormality. [1] This condition primarily involves a reduced ejection fraction (EF) and an enlarged left ventricular end-diastolic volume or diameter. [5] Conceptually, DCM represents a significant cause of systolic heart failure, arising from the heart's inability to pump blood effectively due to weakened and stretched ventricular muscle. [5]
The precise definition of DCM often involves an operational framework that considers structural and functional cardiac changes. It is fundamentally defined by hypocontractility observed on imaging, alongside the characteristic chamber dilation. [9] The presence of such changes, particularly reduced left ventricular ejection fraction, signifies the core physiological trait of the condition, setting the stage for its clinical manifestations and progression towards heart failure. [9] A revised definition has been proposed by the European Society of Cardiology (ESC) working group to further refine understanding and clinical implications. [15]
Diagnostic Criteria and Measurement Approaches
The diagnosis of dilated cardiomyopathy relies on a combination of clinical, imaging, and functional criteria. Key diagnostic measurements typically include an ejection fraction (EF) of ≤40% and a left ventricular end-diastolic dimension (LVEDD) of ≥5.6 cm. [2] These quantitative thresholds, derived from imaging techniques, are crucial for objectively identifying the ventricular dilation and systolic dysfunction characteristic of DCM. [5] Imaging criteria are integral to case definition in clinical cohorts, ensuring a consistent and measurable diagnosis. [9]
Beyond imaging, clinical criteria often include symptoms indicative of heart failure, such as New York Heart Association (NYHA) class III–IV symptoms. [2] For research purposes, particularly in large biobank studies, definitions may be operationalized using International Classification of Disease (ICD) codes. For example, a strict nonischemic dilated cardiomyopathy (NI-DCM) phenotype can be defined using ICD10 code I42.0 ('dilated cardiomyopathy') with the essential exclusion of antecedent acute coronary syndromes and/or revascularization procedures. [9] This exclusionary approach helps differentiate primary DCM from conditions where ventricular dilation is secondary to ischemic heart disease or other identifiable causes. [5]
Classification Systems and Terminology
Dilated cardiomyopathy is classified within broader nosological systems, such as those established by the European Society of Cardiology (ESC) Working Group on Myocardial and Pericardial Diseases. [16] These systems help categorize cardiomyopathies based on their morphological and functional characteristics, aiding in diagnosis and management. [16] DCM can be further subtyped into categories like idiopathic DCM, where no identifiable cause is found, or familial DCM, indicating a genetic predisposition and often the presence of mutations in genes such as MYBPC3, MYH6, TPM1, TNNC1, and TNNI3. [17]
Key terminology also differentiates specific presentations of the condition. "Nonischemic dilated cardiomyopathy" (NI-DCM) is a critical term, used to specify cases where ischemia is not the underlying cause, often identified by ruling out antecedent acute coronary syndromes. [9] A broader term, "nonischemic cardiomyopathy" (NICM), may also be employed, encompassing cases defined by ICD10 code I42.0 and other left heart failure codes, again with exclusions for ischemic events. [9] Standardized vocabularies, including the ICD10 code I42.0, are crucial for consistent data collection and analysis in large-scale studies and clinical practice. [9]
Clinical Presentation and Symptom Progression
Dilated cardiomyopathy (DCM) is a significant underlying cause of heart failure (HF) that is not attributed to ischemic heart disease, frequently manifesting as systolic heart failure. [5] Patients typically experience a range of symptoms reflecting the heart's reduced ability to pump blood effectively, although the specific presentation patterns and severity can vary considerably among individuals. [2] While specific symptoms like dyspnea, fatigue, or peripheral edema are not explicitly detailed in the provided context, the clinical entity of heart failure itself implies these common manifestations, which are central to the classification and management guidelines for cardiomyopathies. [4] The progression of symptoms can range from subtle, insidious onset to severe, advanced stages necessitating intensive medical intervention, highlighting the broad spectrum of clinical phenotypes associated with DCM.
Diagnostic Approaches and Objective Assessment
The definitive diagnosis of dilated cardiomyopathy relies heavily on objective measurement approaches, primarily through advanced cardiac imaging. [9] Echocardiography and cardiac magnetic resonance imaging (MRI) serve as critical diagnostic tools, providing essential evidence of left ventricular hypocontractility and chamber dilation, which are hallmark imaging criteria for establishing a DCM diagnosis. [9] For precise phenotyping in both clinical practice and research studies, specific International Classification of Disease (ICD) codes, such as I42.0 for dilated cardiomyopathy, are utilized, often requiring the careful exclusion of antecedent acute coronary syndromes or revascularization procedures to differentiate DCM from ischemic etiologies. [9] These objective assessments are fundamental for confirming the diagnosis, evaluating disease severity, and guiding appropriate therapeutic strategies.
Phenotypic Heterogeneity and Genetic Insights
Dilated cardiomyopathy demonstrates substantial inter-individual variation and phenotypic diversity, a complexity influenced by the interplay of genetic, environmental, and other non-genetic modifying factors. [2] This heterogeneity implies that similar clinical phenotypes can result from different genetic mutations, and conversely, a mutation within a single gene can lead to diverse clinical subsets of cardiomyopathy across different individuals. [2] Genetic testing and extensive screening are becoming increasingly crucial for diagnosis, especially given that at least 30% of idiopathic DCM cases have a recognized familial component, which serves as an important red flag and potential prognostic indicator. [2] Understanding this complex genetic landscape, alongside considering factors such as age-related changes and sex differences, is vital for refining diagnostic accuracy, predicting disease course, and developing personalized management plans. [7]
Causes
Dilated cardiomyopathy (DCM) is a complex cardiac condition characterized by the enlargement and weakening of the heart's ventricles, leading to impaired pumping function. While approximately half of heart failure cases are not due to ischemic heart disease, DCM represents a significant proportion of these non-ischemic cardiomyopathies. [2] The etiology of DCM is multifactorial, involving a combination of genetic predispositions, environmental exposures, and intricate interactions between these factors, which together influence disease development and progression. [2]
Genetic Predisposition
Genetic factors play a substantial role in the development of dilated cardiomyopathy, with at least 30% of patients having an affected family member, indicating a strong inherited component. [2] Both Mendelian forms, caused by single gene mutations, and polygenic risk, involving multiple genetic variants, contribute to susceptibility. Research highlights genetic heterogeneity, where different gene mutations can lead to the same clinical phenotype, and conversely, mutations in the same gene can manifest as varying clinical subsets of cardiomyopathy across individuals. [2] Genome-wide association studies (GWAS) have been instrumental in identifying numerous susceptibility loci and candidate genes, including HSPB7, BAG3, SLC6A6, SMARCB1, and CAMK2D, which are implicated in cardiac structure, stress response, and calcium handling . [5], [7], [9] For instance, variants in HSPB7, a small heat shock protein selectively expressed in cardiovascular tissues, have been linked to advanced heart failure and systolic dysfunction, while variants in BAG3 are also associated with familial DCM. [7]
Recent GWAS have pinpointed specific chromosomal regions associated with DCM risk, such as 3p25.1, 22q11.23, and 6p21, with specific single-nucleotide polymorphisms (SNPs) like rs62232870, rs4684185, and rs7284877 showing significant associations . [5], [8] These studies reveal that common genetic variants contribute to the overall risk, and polygenic risk scores derived from GWAS can predict DCM susceptibility. [9] While some gene-based analyses in specific populations, such as African Americans, have not yet reached genome-wide significance, the ongoing discovery of diverse genetic players underscores the complex genetic architecture underlying DCM. [2]
Environmental and Lifestyle Factors
Beyond genetics, several environmental and lifestyle factors contribute to the risk of developing dilated cardiomyopathy. Mendelian randomization studies, which use genetic variants as proxies for environmental exposures, have identified several potential causal risk factors. These include elevated body mass index (BMI) and weight, which place increased strain on the cardiovascular system. [9] Furthermore, conditions such as atrial fibrillation (AF) and high systolic blood pressure (SBP) are recognized as independent causal factors for DCM, consistent with their known roles in general heart failure development. [9] While specific dietary patterns or environmental exposures are not explicitly detailed as direct causes in some studies, the identification of these modifiable risk factors highlights the importance of lifestyle in disease prevention and management.
Complex Interactions and Modulating Influences
The development of dilated cardiomyopathy is rarely solely attributable to a single cause, often arising from intricate interactions between genetic predispositions and environmental or other non-genetic modifiers. These gene-environment interactions can significantly influence both the risk of developing DCM and its prognosis. [2] For example, the impact of polygenic risk scores on DCM susceptibility can differ between individuals who carry rare pathogenic variants and those who do not, illustrating how genetic background modulates the effects of common risk variants. [9] The genetic liability to DCM itself is closely linked to systolic heart failure, suggesting that underlying genetic predispositions can modulate the risk of systolic failure across various clinical settings. [9]
Furthermore, the mechanisms by which genetic variants exert their effects often involve developmental and epigenetic regulation. Studies have revealed that DCM-associated genetic loci are frequently found in regions with regulatory DNA features, including histone ChIP-seq signals and DNaseI hypersensitivity sites, which are hallmarks of active gene regulation. [5] These epigenetic marks suggest that the identified genetic variants may influence gene expression and cellular function through altered chromatin states, contributing to the pathology of DCM. While specific early life influences are not detailed, the interplay of genetic susceptibility, environmental triggers like comorbidities (e.g., atrial fibrillation, hypertension), and age-related changes collectively shapes an individual's overall risk and the clinical manifestation of dilated cardiomyopathy. [7]
Biological Background of Dilated Cardiomyopathy
Dilated cardiomyopathy (DCM) is a prevalent cardiac muscle disease characterized by the progressive enlargement of the left ventricle and impaired systolic function, often leading to heart failure. [1] It represents a significant global health burden, affecting individuals across diverse populations. [17] Understanding the intricate biological underpinnings of DCM, from genetic predispositions to cellular dysfunctions and systemic consequences, is crucial for developing effective diagnostic and therapeutic strategies.
Genetic Landscape and Molecular Players in DCM
Dilated cardiomyopathy has a complex genetic etiology, with numerous genes and regulatory elements contributing to its development and progression. [18] Recent genome-wide association studies (GWAS) have identified novel susceptibility loci, including regions on chromosome 3p25.1 and 22q11.23, where SLC6A6 and SMARCB1 have been pinpointed as key culprit genes, respectively. [5] These findings highlight new biological pathways that could serve as targets for therapeutic interventions. [5]
Beyond these newly discovered loci, other genes like HSPB7 and BAG3 have been consistently implicated in DCM. [5] HSPB7, also known as cardiovascular heat shock protein (HSP), exhibits selective expression in cardiac tissues and functions as a small HSP, binding to denatured proteins to maintain cellular proteostasis. [7] Genetic variants in HSPB7 are associated with advanced heart failure and systolic dysfunction. [7] Similarly, variants in BAG3, including common ones like C151R and P407L, are found in familial forms of DCM. [7] The disease also frequently involves rare coding sequence variants in sarcomeric genes such as MYBPC3, MYH6, TPM1, TNNC1, and TNNI3, emphasizing the critical role of the contractile machinery in disease pathogenesis. [6] Other structural genes like TTN, OBSCN, ACTN2, SVIL (an actin-binding protein), and PDLIM5 (a cytoskeletal linker) are also crucial for cardiomyocyte function and contribute to DCM. [9]
Cellular Pathways and Structural Integrity
The proper functioning of cardiomyocytes relies on an intricate network of molecular and cellular pathways that maintain structural integrity and metabolic homeostasis. Protein quality control mechanisms are vital, as exemplified by the role of heat shock proteins; for instance, a dominant mutation in HSPB5 (aB-crystallin) can lead to desmin-related cardiomyopathy characterized by impaired autophagy and the accumulation of misfolded proteins, underscoring the cellular burden when these pathways are compromised. [7] Pathway analyses indicate an enrichment of genes related to primary cardiomyopathy, encompassing both hypertrophic and dilated forms, suggesting common underlying cellular dysfunctions. [2]
Key signaling cascades, such as the cAMP-mediated pathway and the NFAT pathway, are centrally involved in the cellular response to stress and the development of cardiac hypertrophy. [2] Genes like GNAI1, PLCB1, CAMK2B, SRC, CALM1, and various ADCY family members are integral components of these signal transduction events. [2] Furthermore, the precise regulation of intracellular calcium, mediated by voltage-gated L-type calcium channels and proteins like CAMK2D, is indispensable for cardiomyocyte contraction and relaxation; dysregulation in calcium handling can severely impair cardiac function. [9] The structural integrity of the heart is also maintained by the cytoskeleton, with components encoded by genes like TTN, OBSCN, ACTN2, SVIL, and PDLIM5, and disruptions in these elements or related pathways like ERBB signaling contribute to the progressive ventricular dilation characteristic of DCM. [9]
Pathophysiological Progression and Cardiac Dysfunction
Dilated cardiomyopathy is fundamentally a pathophysiological process marked by the progressive enlargement of the cardiac chambers and a decline in the heart's pumping efficiency, ultimately resulting in systolic heart failure. [5] This pathological cardiac remodeling involves significant disruptions to cellular and tissue homeostasis, ranging from altered cellular stress responses to changes in the mechanical properties of the myocardium. [9] For instance, the accumulation of misfolded proteins and impaired autophagy can directly contribute to cardiomyocyte damage and the subsequent functional deterioration of the heart. [7]
The progression of DCM can be influenced by differential gene expression patterns within cardiomyocytes and other cardiac cell types. [9] Genes such as MAP3K7, which is linked to cardiospondylofacial syndrome, and ADAMTS7, a metalloprotease involved in vascular remodeling, exhibit significant differences in expression between DCM and healthy hearts, indicating their involvement in disease mechanisms. [9] Moreover, exposure to certain chemotherapeutic agents, like doxorubicin and docetaxel, can induce DCM-like phenotypes, suggesting that pathways related to apoptosis and aberrant mitosis contribute to myocardial injury and subsequent cardiac dysfunction. [9] Mendelian randomization studies have further identified several potential causal risk factors for DCM, including body weight, body mass index, atrial fibrillation, and systolic blood pressure, underscoring the complex interplay between genetic predispositions and systemic environmental factors in the disease's development. [9]
Regulatory Networks and Systemic Interactions
The development and progression of dilated cardiomyopathy are intricately controlled by complex regulatory networks that govern gene expression and cellular responses across various tissues and cell types. Genetic variants associated with DCM frequently impact regulatory DNA features, such as histone modifications, specific regulatory elements, and binding sites for chromatin-interacting proteins, all of which collectively modulate gene transcription. [5] This regulatory complexity is further highlighted by the cell-type-specific gene expression patterns observed in the heart, where many DCM-prioritized genes show elevated or preferential expression within cardiomyocytes, the heart's primary contractile cells. [9]
Beyond cardiomyocytes, the expression of genes in other cell types, such as macrophages, can also be relevant; for example, DCM-associated single nucleotide polymorphisms (SNPs) have been linked to HSPB7 gene expression in these immune cells, suggesting potential inflammatory contributions and broader tissue interactions in the disease. [7] Transcription factors, such as MITF, which is implicated in cardiac hypertrophy, play a crucial role in orchestrating gene expression programs that can lead to maladaptive cardiac remodeling. [9] Disruptions in key regulatory pathways, such as the hyperactivation of Akt/mTOR signaling observed following the deletion of MLIP, can impair the heart's ability to adapt to stress, ultimately leading to progressive dysfunction. [9] The observed higher prevalence of idiopathic DCM in African Americans, along with documented biological differences in cardiac adaptation to exercise compared to Caucasians, suggests that population-specific genetic backgrounds and their interactions with environmental factors contribute significantly to the varying incidence and progression of the disease. [2]
Cardiac Signaling and Regulatory Networks
Dilated cardiomyopathy (DCM) involves complex dysregulation of cardiac signaling pathways crucial for maintaining heart structure and function. Key among these are the _NFAT_ and _cAMP_-mediated signaling cascades, which play significant roles in regulating cardiac hypertrophy and cellular responses. For instance, _NFAT_ (Nuclear Factor of Activated T-cells) signaling is implicated in the hypertrophic remodeling of the heart, while _cAMP_ (cyclic adenosine monophosphate) pathways involve various components like _GNAI1_, _CAMK2B_, _CALM1_, and _ADCY_ family members, which modulate intracellular processes. [2] Dysregulation in these pathways can lead to aberrant cell growth and impaired contractility, foundational to DCM pathogenesis.
Further, the _Akt/mTOR_ signaling pathway, a central regulator of cell growth and metabolism, is implicated in DCM. Deletion of _MLIP_ (muscle-enriched A-type lamin-interacting protein) has been shown to lead to cardiac hyperactivation of _Akt/mTOR_, which impairs the heart's adaptive responses. [19] Other critical signaling molecules include _MAP3K7_ (encoding TGF-β-activated kinase 1), which is differentially expressed in DCM hearts and linked to cardiospondylocarpofacial syndrome, and _PRKCA_. [9] The transcription factor _MITF_ is also involved, regulating cardiac growth and hypertrophy. [9] Additionally, _ERBB signaling_ has emerged as a distinct pathway associated with DCM. [9]
Cytoskeletal Integrity and Contractile Function
The structural integrity and contractile efficiency of cardiomyocytes are critically dependent on the cytoskeleton and sarcomeric proteins, which are frequently compromised in DCM. Genes encoding components of the contractile apparatus, such as _TTN_, _OBSCN_, and _ACTN2_, are pivotal in DCM pathogenesis, highlighting the importance of normal muscle contraction. [9] Beyond these well-known sarcomeric genes, other structural proteins like _SVIL_ (an actin-binding protein) and _PDLIM5_ (a cytoskeletal linker) also play roles in maintaining cardiomyocyte structure and function. [20] The central role of voltage-gated _L-type calcium channels_ in regulating intracellular _Ca2+_ is also crucial for excitation-contraction coupling in the heart. [2]
Furthermore, small heat shock proteins (sHSPs) like _HSPB7_ are essential for the physiological response of muscle fibers to stress by binding denatured proteins. [7] _HSPB7_ is selectively expressed in cardiovascular tissues and is indispensable for heart development through its role in modulating actin filament assembly. [21] Genetic variants in _HSPB7_ have been associated with advanced heart failure and systolic dysfunction, underscoring its importance in maintaining myocardial function. [7] Mutations in _BAG3_ (Bcl2-associated athanogene 3), another protein involved in protein quality control, can lead to severe forms of desmin-related cardiomyopathy characterized by impaired autophagy and accumulation of misfolded proteins. [22] Genes like _MYH7_ and _SGCD_ have also been linked to idiopathic dilated cardiomyopathy. [2]
Cellular Stress Response and Metabolic Adaptation
The heart's ability to adapt to various stressors and maintain metabolic homeostasis is critical, and dysregulation in these processes contributes significantly to DCM. Cellular stress, particularly ER-stress mediated apoptosis, is a mechanism that can lead to cardiomyopathy. [9] The cytotoxic effects of certain chemotherapeutics like doxorubicin and docetaxel can induce DCM-like phenotypes, highlighting the impact of cellular stress on myocardial health. [9] These observations suggest that the pathways involved in cellular stress responses, protein folding, and programmed cell death are critical in the development and progression of DCM.
Emerging Genetic Factors and Pathway Dysregulation
Recent genome-wide association studies (GWAS) have identified novel genetic susceptibility loci that shed light on additional biological pathways involved in DCM. Two new players, _SLC6A6_ on chromosome 3p25.1 and _SMARCB1_ on chromosome 22q11.23, have been identified through comprehensive genetic analyses. [5] These genes represent potential new therapeutic targets and suggest previously unrecognized pathways contributing to systolic heart failure. [5] Understanding the roles of these emerging genetic factors in the context of broader pathway dysregulation is crucial for developing targeted interventions for DCM.
Diagnostic and Risk Stratification Strategies
Understanding the genetic underpinnings of dilated cardiomyopathy (DCM) is critical for improving diagnostic accuracy and implementing effective risk stratification. Genetic testing plays a vital role in identifying familial cases, given that at least 30% of individuals with idiopathic dilated cardiomyopathy (IDC) have an affected family member. [2] Recent genome-wide association studies (GWAS) have identified novel genetic loci, such as those on chromosomes 3p25.1 and 22q11.23, and specific genes like SLC6A6 and SMARCB1, which shed light on new biological pathways relevant to DCM pathogenesis. [5] These discoveries, alongside the identification of a 6p21 risk locus, offer potential targets for diagnostic assays and therapeutic interventions. [8]
The integration of genetic information into clinical practice extends to personalized medicine approaches, particularly through the development of Polygenic Risk Scores (PRS). A PRS derived from GWAS data has demonstrated utility in predicting DCM risk, even in individuals without rare pathogenic variants. [9] This allows for the identification of high-risk individuals who may benefit from early monitoring and targeted prevention strategies. Furthermore, the assessment of the diagnostic yield of combined cardiomyopathy and arrhythmia genetic testing highlights the complex interplay of cardiac conditions and the need for comprehensive genetic evaluations. [11] Imaging criteria, particularly from cardiac magnetic resonance imaging (MRI), are fundamental for defining clinical DCM cases and offer additional genetic insights, reinforcing a multimodal diagnostic approach. [9]
Prognostic Insights and Disease Progression
Genetic research provides crucial insights into the prognosis and progression of DCM, influencing long-term patient management and potential treatment responses. The genetic liability to DCM is intrinsically linked to systolic heart failure (HF) and can modulate the risk of systolic failure across various clinical settings. [9] Identifying genes such as CAMK2D (involved in calcium handling), MAP3K7 (implicated in cardiospondylofacial syndrome), ADAMTS7 (a thrombospondin-regulating metalloprotease), PRKCA, and MLIP (a lamin-interacting protein) through GWAS helps elucidate the mechanisms underlying DCM and myocardial resilience. [9] These findings offer promising avenues for predicting disease trajectory and understanding individual responses to therapies.
Moreover, studies indicate that pathogenic variants can disrupt cellular composition and single-cell transcription within the heart, providing molecular markers that may correlate with disease severity and progression. [23] The discovery of novel biological pathways through genetic analyses, such as those involving SLC6A6 and SMARCB1, suggests putative new therapeutic targets that could lead to more effective treatments and improved long-term outcomes for patients. [5] By understanding these genetic influences, clinicians can better anticipate disease course, tailor monitoring strategies, and potentially intervene earlier to alter the natural history of DCM.
Associated Conditions and Phenotypic Complexity
DCM is a significant contributor to the global burden of heart failure, accounting for nearly half of all non-ischemic heart failure cases annually. [2] The clinical relevance extends to its associations with various comorbidities and its complex phenotypic presentations. Mendelian randomization studies have identified several common conditions and quantitative traits as potential causal risk factors for DCM, including elevated weight, higher body mass index (BMI), atrial fibrillation (AF), and increased systolic blood pressure (SBP). [9] Notably, AF, weight, and SBP have been confirmed as independent risk factors, underscoring the importance of managing these comorbidities in DCM patients.
The etiology of DCM is often complex, with varying clinical features arising even from specific monogenic mutations; conversely, mutations in the same gene can lead to diverse clinical subsets of cardiomyopathy in different individuals. [2] This variability highlights the critical influence of genetic, environmental, and other non-genetic modifiers on disease expression and progression. Furthermore, research indicates shared genetic pathways between DCM and hypertrophic cardiomyopathy, sometimes with opposing directions of effect, revealing overlapping genetic predispositions to different cardiomyopathy phenotypes. [12] The identification of genes like MAP3K7, which is implicated in syndromic presentations such as cardiospondylofacial syndrome, further emphasizes the intricate connections between DCM and broader systemic conditions. [9]
Frequently Asked Questions About Dilated Cardiomyopathy
These questions address the most important and specific aspects of dilated cardiomyopathy based on current genetic research.
1. My family has weak hearts; will I definitely get it too?
Not necessarily, but your risk is higher. Genetic factors contribute substantially to dilated cardiomyopathy, with about 30% of cases having a familial link and an estimated heritability of 31%. However, it's also influenced by environmental and other non-genetic factors, so having a family history doesn't guarantee you'll develop the condition.
2. If my sibling has heart issues, should I get checked?
Yes, it's a good idea to discuss this with your doctor. Given that genetic factors play a significant role and familial cases are common, understanding your family history is crucial. Genetic testing is increasingly used to assess risk and diagnose heart conditions, which could help guide screening or preventive measures for you.
3. Why do some families seem to have more heart problems?
This often comes down to inherited genetic mutations. Dilated cardiomyopathy can be caused by changes in genes, such as those encoding sarcomeric proteins like MYBPC3 or MYH6, or other genes like HSPB7 and BAG3. When these mutations are passed down through generations, they can increase the likelihood of multiple family members developing heart conditions.
4. Can being overweight really hurt my heart this much?
Yes, your weight can significantly impact your heart health. Research, including Mendelian randomization studies, has identified both weight and body mass index (BMI) as potential causal risk factors for dilated cardiomyopathy. Managing your weight can be an important step in reducing your overall risk for heart failure.
5. Does keeping my blood pressure down protect my heart?
Absolutely, maintaining healthy blood pressure is crucial for your heart. High systolic blood pressure is recognized as a potential causal risk factor for dilated cardiomyopathy. By keeping your blood pressure within a healthy range, you can help protect your heart from developing or worsening conditions like DCM.
6. If I exercise and eat well, can I avoid heart disease?
Healthy lifestyle choices like exercise and good nutrition are very beneficial for your heart, but they might not entirely prevent a genetically predisposed condition. While they can mitigate some risks, genetic factors are substantial contributors to dilated cardiomyopathy. The condition's development is complex, involving a mix of genetic, environmental, and other influences.
7. Is a special DNA test useful for my heart condition?
Yes, genetic testing can be very useful. It's increasingly utilized to help diagnose cardiomyopathy and associated arrhythmia conditions. Identifying specific genetic risk factors can provide a clearer understanding of your condition, help predict its course, and inform personalized management strategies.
8. What do doctors learn from my DNA for heart health?
From your DNA, doctors can identify specific genetic mutations that might be causing or increasing your risk for dilated cardiomyopathy. This can include mutations in genes like MYBPC3, HSPB7, BAG3, SLC6A6, SMARCB1, or CAMK2D. This information helps understand the underlying biological pathways involved and can lead to more targeted care and potential new therapies.
9. Why did my heart fail when I thought I was healthy?
It's a complex situation, and often the exact cause isn't immediately clear. Dilated cardiomyopathy can develop due to a combination of genetic factors, environmental influences, and other non-genetic issues, even in individuals who appear healthy. In many cases, the precise reason remains undetermined, even after extensive medical and genetic screening.
10. My friend and I live similar lives; why is my heart different?
Even with similar lifestyles, genetic differences can play a significant role in heart health. Dilated cardiomyopathy has complex underpinnings, involving a combination of genetic and other influences. Mutations in certain genes can make some individuals more susceptible to the condition, explaining why two people with similar habits might have different heart outcomes.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Jefferies, J. L., and J. A. Towbin. "Dilated cardiomyopathy." Lancet, vol. 375, 2010, pp. 752–762.
[2] Xu, H et al. "A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in African Americans." J Pers Med, 2018.
[3] Everly, M. J. "Cardiac transplantation in the United States: an analysis of the UNOS registry." Clin Transpl, 2008, pp. 35–43.
[4] Arbelo, E. et al. "2023 ESC Guidelines for the management of cardiomyopathies." Eur Heart J, vol. 44, 2023, pp. 3503–3626.
[5] Garnier, S et al. "Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23." Eur Heart J, 2021.
[6] Hershberger, R. E. et al. "Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy." Circ Cardiovasc Genet, vol. 3, 2010, pp. 155–161.
[7] Villard, E et al. "A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy." Eur Heart J, 2011.
[8] Meder, B et al. "A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy." Eur Heart J, 2014.
[9] Jurgens, S. J. et al. "Genome-wide association study reveals mechanisms underlying dilated cardiomyopathy and myocardial resilience." Nat Genet, vol. 56, 2024, pp. 2636–2645.
[10] Aragam, K. G. et al. "Phenotypic refinement of heart failure in a national biobank facilitates genetic discovery." Circulation, vol. 139, 2019, pp. 489–501.
[11] Dellefave-Castillo, L. M. et al. "Assessment of the diagnostic yield of combined cardiomyopathy and arrhythmia genetic testing." JAMA Cardiol, vol. 7, 2022, pp. 966–974.
[12] Tadros, R., et al. "Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect." Nat Genet, vol. 53, 2021, pp. 128–134.
[13] Lee, S. H., et al. "Estimating missing heritability for disease from genome-wide association studies." American Journal of Human Genetics, vol. 88, no. 3, 2011, pp. 294–305.
[14] Harper, Alice R., et al. "Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity." Nature Genetics, 2021.
[15] Pinto, Y. M., et al. "Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases." Eur Heart J, vol. 37, 2016, pp. 1850–1858.
[16] Elliott, P., et al. "Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases." Eur Heart J, vol. 29, 2007, pp. 270–276.
[17] Codd, M. B. et al. "Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984." Circulation, vol. 80, 1989, pp. 564–572.
[18] Rampersaud, E et al. "Common susceptibility variants examined for association with dilated cardiomyopathy." Ann Hum Genet, 2010.
[19] Cattin, M.-E., et al. "Deletion of MLIP (muscle-enriched A-type lamin-interacting protein) leads to cardiac hyperactivation of Akt/mammalian target of rapamycin (mTOR) and impaired cardiac adaptation." J. Biol. Chem., vol. 290, 2015, pp. 26699–26714.
[20] Huang, X., et al. "An overview of the cytoskeleton-associated role of PDLIM5." Front. Physiol., vol. 11, 2020, p. 975.
[21] Wu, T., et al. "HSPB7 is indispensable for heart development by modulating actin filament assembly." Proc. Natl Acad. Sci. USA, vol. 114, 2017, pp. 11956–11961.
[22] Odgerel, Z., et al. "Inheritance patterns and phenotypic features of myofibrillar myopathy associated with a BAG3 mutation." Neuromuscul Disord., vol. 20, 2010, pp. 438–442.
[23] Reichart, David et al. "Pathogenic variants damage cell composition and single cell transcription in cardiomyopathies." Science, vol. 377, 2022, p. eabo1984.